Relationship between gestational age and endoglin levels in maternal and cord blood

Simmi Kharb, R. Tiwari, S. Nanda


Background: Poor placentation at early gestational age is an important predisposing condition for the development of preeclampsia. The present study was designed to study the relationship of gestational age with endoglin levels in maternal and cord blood of normal and pre-eclamptic women.

Methods: The present study was conducted in fifty pregnant women that were grouped as: group 1 (control, n=25) comprising of normotensive women immediately after delivery, group 2 (study group, n=25) comprising of age -and sex- matched pre-eclamptic women. Study samples were drawn (maternal venous blood and umbilical cord blood). Endoglin was analyzed by competitive enzyme linked immunosorbent assay.

Results: Maternal serum endoglin levels were decreased in group II as compared to group I. Maternal endoglin showed a positive correlation with gestational age in both normotensive and preeclamptic women. Cord blood endoglin showed negative correlation with gestational age in both normotensive women and preeclamptics. A significant positive correlation was found between maternal and cord blood endoglin levels with birth weight in preeclamptic mothers. Pre-eclamptics with birth weight less than 2.5 kg had lower maternal blood endoglin levels as compared to controls.

Conclusions: These finding suggest that endoglin levels may responsible for the pathogenesis of PE and/or IUGR.


Endoglin, Gestational age, Pregnancy, Preeclamptics, Cord blood

Full Text:



Chaiworapongsa T, Romero R, Kusanovic JP, Mittal P, Kim SK, Gotsch F et al. Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations. Ultrasound Obstet Gynecol. 2010;35:155-62.

Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-58.

Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM et al. Soluble endoglin contributes to the atherogenesis of preeclampsia. Nature Med. 2006;12:642-9.

Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592-4.

Kapur NK, Morine KJ, Letarte M. Endoglin: a critical mediator of cardiovascular health. Vasc Health Risk Manag. 2013;9:195-206.

Alt A, Miguel-Romero L, Donderis J, Aristorena M, Blanco FJ, Round A et al. Structural and functional insights into endoglin ligand recognition and binding. PLoS One. 2012;7(2):e29948.

Castonguay R, Werner ED, Matthews RG, Presman E, Mulivor AW, Solban N et al. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem. 2011;286:30034-46.

Cudmore MJ, Ahmad S, Sissaoui S, RammaW, Ma Bin, Fujisawa T et al. Loss of Akt activity increases circulating soluble endoglin release in preeclampsia: identification of inter-dependency between Akt-1 and heme oxygenase-1. Eur Heart J. 2012;33:1150-8.

Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble VEGF receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small-for-gestational-age neonate. J Matern Fetal Neonatal Med. 2008;21:9-23.

Barker DJ. Intrauterine programmes of coronary heart disease and stroke. Acta Paediatr. 1997;423:178-82.

Haladay A. Early risk factors for cardiovascular disease. BNF Nutr Bull. 1990;15:6-7.

Barker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME. Growth in utero blood pressure in childhood and adult life and mortality from cardiovascular disease. BMJ. 1989;298:564-7.

Barker DJP, Hunter PD, Osmonde, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. Lancet. 1989;9:577-80.

Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-83.

Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee KY, Goncalves LF, Gomez R, Edwin S. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young investigator award. Am J Obstet Gynecol. 2004;190:1541-7.

Gotsch F, Kim YM, Kim CJ, Edwin S, Holtra J, Tarca AL et al. A link between inflammation/infection and anti-angiogenic state in preeclampsia: inflammatory mediators mimic effect of hypoxia on trophoblast by increasing sFlt-1 and decreasing placental growth factor production. International Society for the Study of Hypertension in Pregnancy 2009 World Congress XVI, Washington, DC, USA. 2008;46.

Yinon Y, Nevo O, Xu J, Many A, Rolfo A, Todros T et al. Severe intrauterine growth restriction pregnancies have increased placental endoglin levels. Am J Pathol. 2008;172:77–85.

Laskowska M, Laskowska K, Oleszczuk J. Endoglin in pregnancy complicated by fetal intrauterine growth restriction in normotensive and pre-eclamptic pregnant women: a comparison between pre-eclamptic patients with appropriate-for-gestational-age weight infants and healthy pregnant women. J Matern Fetal Neonatal Med. 2012;25:806-11.

Szentpéteri I, Rab A, Kornya L, Kovács P, Brubel B, Joó JG. Placental gene expression patterns of endoglin (CD105) in intrauterine growth restriction. Mat Fe Neo Med. 2014;27:350-4.

Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592-4.